The Law Offices of Frank R. Cruz filed the complaint, asserting that Embecta executives provided unattainable financial guidance throughout the specified period. According to the filing, the company allegedly obscured significant weakness within the United States pen needle market, which ultimately undermined its second-quarter 2026 projections. Plaintiffs argue that these omissions rendered public statements regarding the company's business operations materially misleading.

Those who purchased shares during this window retain the right to participate in the litigation or choose independent counsel. Potential lead plaintiffs must submit their intent to the court by the August deadline. The firm is currently collecting inquiries from affected shareholders via email and phone to facilitate participation in the ongoing legal proceedings.